Compare GBTG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBTG | TNGX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2020 | 2020 |
| Metric | GBTG | TNGX |
|---|---|---|
| Price | $5.70 | $25.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $8.92 | ★ $20.00 |
| AVG Volume (30 Days) | 1.2M | ★ 2.7M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 173.33 | 26.89 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $2,718,000,000.00 | $62,384,000.00 |
| Revenue This Year | $21.78 | N/A |
| Revenue Next Year | $4.32 | N/A |
| P/E Ratio | $26.86 | ★ N/A |
| Revenue Growth | 12.17 | ★ 48.29 |
| 52 Week Low | $4.96 | $1.04 |
| 52 Week High | $8.64 | $28.41 |
| Indicator | GBTG | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 48.16 | 64.91 |
| Support Level | $5.20 | $6.54 |
| Resistance Level | $5.88 | N/A |
| Average True Range (ATR) | 0.25 | 1.62 |
| MACD | 0.03 | 0.27 |
| Stochastic Oscillator | 40.49 | 69.08 |
Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.